Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 1/20 | 0.36 |
| ▸ | LAP3 | P28838 | 3/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | PGK2 | P07205 | 1/20 | 0.35 |
| ▸ | GLUL | P15104 | 1/20 | 0.35 |
| ▸ | GCLC | P48506 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Threonine SCHEMBL6937630 | 0.93 | LAP3 (0.40) | LAP3PGK1PGK2GLULGCLC | |
| SCHEMBL60701 | 0.81 | GLUL (0.48) | PGK1PGK2GLUL | |
| SCHEMBL1332612 | 0.81 | GLUL (0.48) | PGK1PGK2GLUL | |
| SCHEMBL27427521 | 0.79 | SLC7A5 (0.45) | SLC7A5 | |
| SCHEMBL6033505 | 0.79 | SLC7A5 (0.45) | SLC7A5 | |
| Dexfosfoserine SCHEMBL28403275 | 0.78 | PGK1 (0.50) | PGDLAP3PGK1PGK2 | |
| Phosphocholine SCHEMBL8602718 | 0.74 | SMN1; SMN2 (0.39) | PGDLAP3PGK1PGK2SLC7A5 | |
| Phosphocholine SCHEMBL8602065 | 0.74 | SMN1; SMN2 (0.39) | PGDLAP3PGK1PGK2SLC7A5 | |
| Threonine SCHEMBL6937624 | 0.73 | GLUL (0.42) | GLULGCLC | |
| Threonine SCHEMBL382179 | 0.73 | GLUL (0.42) | GLULGCLC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101386-B2 | Escherichia coli strains which over-produce L-threonine and processes for the production of L-threonine by fermentation | ARCHER DANIELS MIDLAND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1322765-B1 | ESCHERICHIA COLI/ STRAINS WHICH OVER-PRODUCE L-THREONINE AND PROCESSES FOR THE PRODUCTION OF L-THREONINE BY FERMENTATION | ARCHER DANIELS MIDLAND CO (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20100267095-A1 | ESCHERICHIA COLI STRAINS WHICH OVER-PRODUCE L-THREONINE AND PROCESSES FOR THE PRODUCTION OF L-THREONINE BY FERMENTATION | LIAW HUNGMING J | 2010-10-21 | — | — | US | disclosed |
| US-7767431-B2 | Escherichia coli strains which over-produce L-threonine and processes for the production of L-threonine by fermentation | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100159537-A1 | ESCHERICHIA COLI STRAINS THAT OVER-PRODUCE L-THREONINE AND PROCESSES FOR THEIR PRODUCTION | D ELIA JOHN N | 2010-06-24 | — | — | US | disclosed |
| US-7723097-B2 | Escherichia coli strains that over-produce L-threonine and processes for their production | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2010-05-25 | — | — | US | disclosed |
| US-7687253-B2 | Escherichia coli strains which over-produce L-threonine and processes for the production of L-threonine by fermentation | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2010-03-30 | — | — | US | disclosed |
| EP-0917578-B1 | NOVEL STRAINS OF ESCHERICHIA COLI, METHODS OF PREPARING THE SAME AND USE THEREOF IN FERMENTATION PROCESSES FOR L-THREONINE PRODUCTION | ARCHER DANIELS MIDLAND CO (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080166788-A1 | Escherichia Coli Strains which Over-Produce L-Threonine and Processes for the Production of L-Threonine by Fermentation | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2008-07-10 | — | — | US | disclosed |
| US-20070254337-A1 | Escherichia coli strains which over-produce L-threonine and processes for the production of L-threonine by fermentation | ARCHER- DANIELS-MIDLAND COMPANY (US) | 2007-11-01 | — | — | US | disclosed |
| US-7220571-B2 | Escherichia coli strains which over-produce L-threonine and processes for the production of L-threonine by fermentation | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060205044-A1 | Escherichia coli strains that over-produce L-threonine and processes for their production | ARCHER-DANIELS-MIDLAND COMPANY | 2006-09-14 | — | — | US | disclosed |
| US-20020106800-A1 | Escherichia coli strains which over-produce L-thereonine and processes for the production of L-threonine by fermentation | ARCHER-DANIELS-MIDLAND COMPANY | 2002-08-08 | — | — | US | disclosed |
| US-5939307-A | GENETIC ENGINEERING | THE ARCHER-DANIELS-MIDLAND COMPANY (US) | 1999-08-17 | — | — | US | disclosed |
| EP-0917578-A1 | NOVEL STRAINS OF $i(ESCHERICHIA COLI), METHODS OF PREPARING THE SAME AND USE THEREOF IN FERMENTATION PROCESSES FOR L-THREONINE PRODUCTION | ARCHER-DANIELS-MIDLAND COMPANY (US) | 1999-05-26 | — | — | EP | disclosed |
| WO-1998004715-A9 | NOVEL STRAINS OF ESCHERICHIA COLI, METHODS OF PREPARING THE SAME AND USE THEREOF IN FERMENTATION PROCESSES FOR L-THREONINE PRODUCTION | — | 1998-05-22 | — | — | WO | disclosed |
| WO-1998004715-A1 | NOVEL STRAINS OF ESCHERICHIA COLI, METHODS OF PREPARING THE SAME AND USE THEREOF IN FERMENTATION PROCESSES FOR L-THREONINE PRODUCTION | ARCHER-DANIELS-MIDLAND COMPANY (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100159537-A1 | ESCHERICHIA COLI STRAINS THAT OVER-PRODUCE L-THREONINE AND PROCESSES FOR THEIR PRODUCTION | TKT, MRPL21, ALDH7A1 | PGD 120/4885LAP3 588/4885PGK1 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.